Sign in or create an account to add this stock to your watchlist.
About BELLUS Health (TSE:BLU)
BELLUS Health Inc., a biopharmaceutical company, engages in developing novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various other partnered clinical-stage drug development programs, including KIACTA, a novel drug candidate for the treatment of patients suffering from active pulmonary sarcoidosis; AMO-01 for Fragile X Syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is based in Laval, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-36.21%
Return on Assets-32.88%
BELLUS Health (TSE:BLU) Frequently Asked Questions
What is BELLUS Health's stock symbol?
BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."
How were BELLUS Health's earnings last quarter?
BELLUS Health Inc. (TSE:BLU) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The company earned $0.42 million during the quarter, compared to analyst estimates of $1 million. BELLUS Health had a negative net margin of 7,295.45% and a negative return on equity of 36.21%. View BELLUS Health's Earnings History.
When is BELLUS Health's next earnings date?
Who are some of BELLUS Health's key competitors?
Some companies that are related to BELLUS Health include ImmunoVaccine (IMMVF), Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford BioDynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP) and Medicure (MPH).
Who are BELLUS Health's key executives?
BELLUS Health's management team includes the folowing people:
- Mr. Roberto Bellini, Chief Exec. Officer, Pres and Director (Age 38)
- Mr. François Desjardins CPA, CA, VP of Fin. (Age 55)
- Dr. Denis Garceau Ph.D., Sr. VP of Drug Devel. (Age 61)
- Mr. Tony Matzouranis, VP of Bus. Devel. (Age 45)
- Mr. Sébastien Roy, Corp. Sec. (Age 42)
Has BELLUS Health been receiving favorable news coverage?
News stories about BLU stock have been trending positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BELLUS Health earned a news impact score of 0.33 on Accern's scale. They also gave news articles about the company an impact score of 46.06 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of BELLUS Health?
Shares of BLU and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is BELLUS Health's stock price today?
One share of BLU stock can currently be purchased for approximately C$0.60.
How big of a company is BELLUS Health?
BELLUS Health has a market capitalization of C$53.77 million.
How can I contact BELLUS Health?
BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.
MarketBeat Community Rating for BELLUS Health (BLU)MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe BLU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLU will underperform the S&P 500 over the long term. You may vote once every thirty days.
BELLUS Health (TSE:BLU) Earnings History and Estimates Chart
BELLUS Health (TSE BLU) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2018|| || || || || || || || |
|2/21/2018||Q4 2017||C($0.02)||C($0.03)||C$0.02 million||View||N/A|
|11/8/2017||Q3 2017||C($0.03)||C$0.09 million||View||N/A|
|5/9/2017||Q1 2017||C$0.02||C$0.01 million||View||N/A|
|3/1/2017||Q4 2016||C($0.02)||C($0.01)||C$0.36 million||View||N/A|
|11/10/2016||Q3 2016||C($0.01)||C($0.01)||C$0.45 million||C$0.36 million||View||N/A|
|8/9/2016||Q2 2016||C($0.01)||C($0.01)||C$0.45 million||C$0.59 million||View||N/A|
|5/12/2016||Q1 2016||C($0.01)||C($0.01)||C$0.40 million||C$0.59 million||View||N/A|
|2/25/2016||Q4 2015||C($0.01)||C$0.02||C$0.80 million||C$2.05 million||View||N/A|
|8/12/2015||Q2 2015||C($0.01)||C($0.01)||C$0.70 million||C$0.59 million||View||N/A|
|11/5/2014||Q3 2014||C($0.02)||C($0.01)||C$0.50 million||C$0.42 million||View||N/A|
|8/13/2014||C($0.02)||C($0.02)||C$1.00 million||C$0.42 million||View||N/A|
|5/7/2014||Q1 2014||C($0.01)||C$0.48 million||View||N/A|
|2/26/2014||Q4 2013||C($0.01)||C$0.75 million||View||N/A|
|11/5/2013||Q3 2013||C$0.02||C$0.53 million||View||N/A|
|8/7/2013||Q2 2013||C($0.02)||C$0.38 million||View||N/A|
|5/15/2013||Q1 2013||C($0.01)||C$0.60 million||View||N/A|
BELLUS Health (TSE:BLU) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
BELLUS Health (TSE BLU) Insider Trading and Institutional Ownership History
BELLUS Health (TSE BLU) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
BELLUS Health (TSE BLU) News Headlines
|BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018|
finance.yahoo.com - May 16 at 11:05 AM
|BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity|
finance.yahoo.com - April 30 at 3:33 PM
|Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix and Crescita Therapeutics|
finance.yahoo.com - April 4 at 12:41 PM
|Dairy Alternatives Market Worth $35.06 Billion by 2024 | CAGR: 16.6%: Grand View Research, Inc.|
www.prnewswire.com - March 15 at 3:41 PM
|Healthcare Trust of America, Inc. Announces Appointment of Roberta B. Bowman to the Company's Board of Directors|
www.bizjournals.com - March 15 at 3:41 PM
|Anthem Blue Cross Medicare Solutions Center Opens in Chinatown|
www.bizjournals.com - March 13 at 11:52 AM
|Bellus Health: Coughing Its Way To Being Swallowed By Big Pharma|
seekingalpha.com - March 2 at 3:42 PM
|BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017|
finance.yahoo.com - February 21 at 11:13 AM
|Bill would mandate greater oversight of health plan mergers|
www.bizjournals.com - February 8 at 5:13 PM
|Canadian Exchanges Stock Scanner, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - January 24 at 8:33 AM
|Research Reports on BELLUS Health Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - December 26 at 8:56 AM
|BELLUS Health Closes $20M Common Share Financing|
finance.yahoo.com - December 12 at 10:01 AM
|IIROC Trade Resumption - BELLUS Health Inc.|
finance.yahoo.com - December 5 at 10:17 AM
|IIROC Trade Resumption - BLU|
finance.yahoo.com - December 5 at 10:17 AM
|BELLUS Health Announces Overnight Marketed Equity Offering|
finance.yahoo.com - December 4 at 5:14 PM
|BELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 14, 2017|
finance.yahoo.com - November 14 at 5:06 PM
|BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2017|
finance.yahoo.com - November 8 at 3:59 PM
|Echo Health Ventures Welcomes Nanette DeTurk and Kent Marquardt to the Company's Advisory Board|
globenewswire.com - October 24 at 11:42 PM
|Bham health care real estate firm expands|
www.bizjournals.com - October 24 at 11:42 PM
|BELLUS Health Inc (BLU) Director Pierre Larochelle Buys 275,000 Shares|
www.americanbankingnews.com - October 3 at 11:16 PM
|BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors|
finance.yahoo.com - October 2 at 12:59 PM
|BELLUS Health (BLUSF) Updates On BLU-5937 & Chronic Cough Key Opinion Leader Event - Slideshow|
seekingalpha.com - September 21 at 4:23 PM
|BELLUS Health Chronic Cough Webcast Taking Place Today|
finance.yahoo.com - September 20 at 5:22 PM
|BRIEF-Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models|
www.reuters.com - September 18 at 4:57 PM
|BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models|
finance.yahoo.com - September 18 at 4:57 PM
|Report Coverage on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - September 14 at 5:15 PM
|BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017|
finance.yahoo.com - September 6 at 4:38 PM
|BELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017|
finance.yahoo.com - August 15 at 5:27 PM
|BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017|
finance.yahoo.com - August 9 at 4:48 PM
|Research Initiated on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - August 7 at 5:08 PM
|BELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 4, 2017|
finance.yahoo.com - August 4 at 9:57 PM
|BELLUS Health Inc (BLU) Set to Announce Quarterly Earnings on Tuesday|
www.americanbankingnews.com - August 1 at 7:31 AM
|Roberto Bellini Buys 225,000 Shares of BELLUS Health Inc (TSE:BLU) Stock|
www.americanbankingnews.com - July 18 at 4:18 PM
|BELLUS Health Inc. (BLU.TO)|
finance.yahoo.com - July 9 at 4:29 PM
|BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M|
finance.yahoo.com - July 3 at 4:39 PM
|Active Wall Street: Research Reports Initiated on Healthcare Stocks BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
www.finanznachrichten.de - June 3 at 5:04 AM
|Bellus posts 1Q profit|
marketbeat.com - May 10 at 5:20 AM
|IIROC Trading Halt - BLU|
www.bizjournals.com - March 1 at 8:49 AM
|Canadian Stocks Are Rising As Brexit Looks Unlikely -- Canadian Commentary|
www.nasdaq.com - June 22 at 8:38 AM
|Savaria, Premium at 52-Week Highs|
www.baystreet.ca - May 5 at 1:43 PM
|Study Reached 120 Qualifying Events, Top-Line Results Expected in Q2 2016|
globenewswire.com - January 21 at 10:13 AM
BELLUS Health (TSE:BLU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
BELLUS Health (TSE BLU) Stock Chart for Thursday, May, 24, 2018